英硅智能(03696)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作

智通财经01-05

智通财经APP讯，英硅智能(03696)公布，集团已与一家由基金会管理的全球独立制药公司施维雅达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及开发符合既定标准的潜在候选...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601832078?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-05 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601832078","market":"hk","top_or_hot":-1,"title":"英硅智能(03696)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作","media":"智通财经","content":"<div>\n<p>智通财经APP讯，英硅智能(03696)公布，集团已与一家由基金会管理的全球独立制药公司施维雅达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及开发符合既定标准的潜在候选...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388402.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英硅智能(03696)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英硅智能(03696)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 08:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1388402.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，英硅智能(03696)公布，集团已与一家由基金会管理的全球独立制药公司施维雅达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及开发符合既定标准的潜在候选...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388402.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1388402.html","article_id":"2601832078","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601832078","pubTimestamp":1767571577,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，英硅智能 公布，集团已与一家由基金会管理的全球独立制药公司施维雅达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03696":"英矽智能"},"translate_title":"Yingsi Intelligent (03696) and Servier reached a multi-year anti-tumor drug research and development cooperation worth US $888 million","themeId":"553701c0628857e3aa8ad30c26408e63","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1.5},"content_text":"智通财经APP讯，英硅智能(03696)公布，集团已与一家由基金会管理的全球独立制药公司施维雅达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及开发符合既定标准的潜在候选药物，而施维雅将共同承担研发成本，主导后续临床验证及商业化进程。施维雅研究所执行董事Christophe Thurieau表示：“此次合作彰显了施维雅致力于运用尖端技术解决尚未被满足的医疗需求，并最终造福患者的承诺，也体现了我们对英硅智能自主研发并经过验证的人工智能平台的信心。”英硅智能创始人、首席执行官兼首席商务官Alex Zhavoronkov博士表示：“我对这次合作感到非常兴奋，这表明我们的人工智能药物研发能力与实力再次获得认可。随着我们将生成式人工智能更深入地融入药物研发价值链的各个阶段，我相信制药超级智慧的未来近在眼前，即AI智能体能够真正做出决策并设计实验，形成推动药物研发更快、更智慧、更安全的良性循环。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601832078","isCrawlerRequest":true}